Form 4: Bio-Key International Executive Receives Stock Grant

Mira LaCous, Chief Technology Officer of Bio-Key International, acquired 9,000 shares of common stock on July 31, 2024, as part of a restricted stock grant.

Summary

• Mira LaCous, the Chief Technology Officer of Bio-Key International, acquired 9,000 shares of common stock on July 31, 2024.
• The acquisition was a result of a restricted stock grant under the Issuer's 2023 Stock Incentive Plan.
• The shares vest in three equal annual installments, contingent upon continued employment with Bio-Key International.
• Following the transaction, LaCous directly owns 10,480 shares of common stock.
• LaCous also holds options to purchase 174 shares, which are not included in the reported holdings.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The stock grant aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Technology Officer.

Risks

• The vesting of the shares is contingent upon continued employment, creating a potential risk if the executive leaves the company before full vesting.

Industry Context

Stock grants are a common practice in the technology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the technology sector.
• Companies like Okta, CrowdStrike, and Ping Identity also utilize stock options and restricted stock units to align executive incentives with shareholder value.
• The vesting schedule of three years is also standard practice.

Stakeholder Impact

• The stock grant aligns the executive's interests with those of the shareholders, potentially leading to better company performance.
• Employees may view the grant positively as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Bio-Key International, BKYI, stock grant, restricted stock, insider trading, Form 4, Mira LaCous, Chief Technology Officer